Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New assay technologies for high-throughput screening

L Silverman1, R Campbell, J R Broach

  • 1Cadus Pharmaceutical Corporation, Tarrytown, NY 10591-6705, USA.

Current Opinion in Chemical Biology
|August 6, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol.

European journal of cancer (Oxford, England : 1990)·2021
Same author

Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol.

Leukemia·2017
Same author

Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol.

Leukemia·2015
Same author

Epigenetic and molecular signatures of cord blood CD34(+) cells treated with histone deacetylase inhibitors.

Vox sanguinis·2015
Same author

Progress report on Harvard-American Iron and Steel Institute research project.

TID [reports]. U.S. Atomic Energy Commission·2014
Same author

Development of an ionization detector for the measurement of aerosol particle concentrations.

TID [reports]. U.S. Atomic Energy Commission·2014
Same journal

Function through shape: An overview of DNA G-quadruplexes in transcriptional regulation.

Current opinion in chemical biology·2026
Same journal

Advances in tools and technologies for multiplexed bioluminescence imaging.

Current opinion in chemical biology·2026
Same journal

High-resolution molecular mapping by expansion-coupled label-free and multimodal imaging.

Current opinion in chemical biology·2026
Same journal

Recent advances in glycoconjugate-based therapeutics.

Current opinion in chemical biology·2026
Same journal

Towards better red emitters for bioimaging: Innovations in rhodamine and cyanine chemistry.

Current opinion in chemical biology·2026
Same journal

Chemigenetic fluorescent biosensors in biological imaging - New trends and advances.

Current opinion in chemical biology·2026
See all related articles

High-throughput screening assays are crucial for drug discovery. Advances in homogeneous, cell-based, and miniaturized assays enable faster identification of potential drug compounds.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • High-throughput screening (HTS) is essential for early-stage drug discovery.
  • Assay format selection is critical for HTS success.
  • Traditional assays face limitations in speed and sensitivity.

Purpose of the Study:

  • To review advancements in assay technologies for high-throughput screening.
  • To highlight methods enabling efficient drug lead identification.
  • To discuss the impact of assay innovation on drug discovery.

Main Methods:

  • Utilizing homogeneous cell-free assays (e.g., energy transfer, fluorescence polarization, fluorescence correlation spectroscopy).
  • Adapting novel cell-based assays for in situ biological target analysis.

Related Experiment Videos

  • Implementing assay miniaturization for ultra-high-throughput screening.

    • Main Results:

    • Homogeneous assays offer sensitivity, speed, and compound interference resistance for HTS.
    • Cell-based assays provide in situ analysis capabilities.
    • Miniaturization facilitates ultra-high-throughput screening.

    Conclusions:

    • Assay technology advancements are critical for efficient drug discovery.
    • Homogeneous and cell-based assays meet HTS requirements.
    • Ultra-high-throughput screening ensures lead identification is not a bottleneck.